Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What

Trial Details

NCT ID
NCT07227298
Phase
PHASE1 / PHASE2
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • PF-08634404
  • Sigvotatug Vedotin
  • Combination Agent 1
Locations (sample)
  • Fayetteville, Arkansas, United States|36.06258,-94.15743
  • Rogers, Arkansas, United States|36.33202,-94.11854
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Fullerton, California, United States|33.87029,-117.92534
  • Fullerton, California, United States|33.87029,-117.92534

Key Eligibility Criteria

  • Pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC and are not a candidate for com…
  • PD-L1 status available
  • Part B only: PD-L1 ≥ TPS 1%
  • Measurable disease based on RECIST v1.1 per investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →